Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging

Experimental Biology and Medicine

Volumn 234, Issue 8, 2009, Pages 860-879

  Alexe, Gabriela ^a,b   Monaco, James ^c   Doyle, Scott ^c   Basavanhally, Ajay ^c   Reddy, Anupama ^d   Seiler, Michael ^d   Ganesan, Shridar ^e   Bhanot, Gyan ^b,d,e   Madabhushi, Anant ^b  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Clinically relevant tumor subtypes; Computerized image analysis; Diagnostic and prognostic markers; Microarray analysis of tumors; PCA and consensus ensemble clustering

Indexed keywords

CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; ONCOPROTEIN; PROTEIN IKBKE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; DRUG TARGETING; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; SHORT SURVEY; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 68149132981     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0902-MR-89     Document Type: Short Survey

References (74)

1. Anim JT, John B, Abdulsathar SS, Prasad A, Saji T, Akhtar N, Ali V, Al-Saleh M. Relationship between the expression of various markers and prognostic factors in breast cancer. Acta Histochem 107:87-93, 2005.
2. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984, 2001.
3. Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304:604-619, 2005.
4. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002.
5. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 406:747-752, 2000.
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874, 2001.
8. Alexe G, Dalgin GS, Ramaswamy R, DeLisi C, Bhanot G. Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns. Cancer Inform 2:243-274, 2006.
9. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7:127, 2006.
10. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003.
11. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4(3):R3, 2002.
12. Bertucci F, Eisinger F, Houlgatte R, Viens P, Birnbaum D. Gene-expression profiling and identification of patients at high risk of breast cancer. Lancet 360:173-174, 2002.
13. Gosset WS. The probable error of a mean. Biometrika 6:1-25, 1908.
14. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121, 2001.
15. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537, 1999.
16. Lyons-Weiler J, Patel S, Becich MJ, Godfrey TE. Tests for finding complex patterns of differential expression in cancers: towards individualized medicine. BMC Bioinformatics 5:110, 2004.
17. Alexe G, Hammer PL. Spanned patterns for the logical analysis of data. Discrete Appl Math 154:1039-1049, 2006.
18. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, Harris L, Barnard N, Martel M, Levine AJ, Ganesan S, Bhanot G. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67(22):10669-10676, 2007.
19. Dalgin GS, Alexe G, Scanfeld D, Tamayo P, Mesirov JP, Ganesan S, DeLisi C, Bhanot G. Portraits of breast cancer progression. BMC Bioinformatics 8:291, 2007.
20. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005.
21. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100:5974-5979, 2003.
22. Monti S, Tamayo P, Mesirov JP, Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 52(1-2):91-118, 2003.
23. Strehl A, Ghosh J. Cluster ensembles: a knowledge reuse framework for combining partitioning. J Mach Learn Res 3:583-617, 2002.
24. Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a dataset via the Gap statistic. J R Stat Soc Series B 63, part 2:411-423, 2001.
25. Kaufmann L, Rousseeuw PJ. Finding Groups in Data: An introduction to cluster analysis. Hoboken, NJ: John Wiley & Sons, 1990, 2005.
26. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006.
27. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468, 2005.
28. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655, 2004.
29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550, 2005.
30. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207, 2007.
31. Boehm JS, Zhao JJ, Yao J, Kim S-Y, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079, 2007.
32. Richardson A, Wang Z, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart J, Livingston D, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121-132, 2006.
33. Ivshina A, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JEL, Liu ET, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292-10301, 2007.
34. Biswas DK, Shi Q, Bailey S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101:10137-10142, 2004.
35. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 6:1973-1982, 2007.
36. Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI, Menard S. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 14:85-94, 1996.
37. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49, 1991.
38. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213, 2003.
39. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666, 2005.
40. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006.
41. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326-8331, 2005.
42. Dranoff G. The therapeutic implications of intratumoral regulatory T cells. Clin Cancer Res 11:8226-8229, 2005.
43. Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol 181:200-206, 1997.
44. Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 59:972-977, 2006.
45. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, Lebecque S. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10:7466-7474, 2004.
46. Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol 111:69-81, 2004.
47. Georgiannos SN, Renaut A, Goode AW, Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cellmediated immune mechanisms, and their association with prognostic indicators. Surgery 134:827-834, 2003.
48. Lee AH, Happerfield LC, Millis RR, Bobrow LG. Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast. Br J Cancer 74:796-801, 1996.
49. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9(1):R15, 2007.
50. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319-326, 2007.
51. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8:258, 2007.
52. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235-244, 2007.
53. Morris SR, Carey LA. Gene expression profiling in breast cancer. Curr Opin Oncol 19:547-551, 2007.
54. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002.
55. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Path 29(9):1228-1242, 2005.
56. Doyle S, Madabhushi A, Feldman M, Tomaszewski J. A boosting cascade for automated detection of prostate cancer from digitized histology. MICCAI 4191:504-511, 2006.
57. Freund Y, Schapire R. Experiments with a new boosting algorithm. In: Saitti L, Ed., Proceedings of the Thirteenth International Conference, on Machine Learning, July 3-6, 1996, Bari, Italy, pp148-156, 1996.
58. Kumar V, Fausto N, Abbas A. Robbin & Cotran Pathologic Basis of Disease (7th ed.). Philadelphia: Elsevier, 2005.
59. Geman S, Geman D. Stochastic relaxation, Gibbs Distribution, and the Bayesian restoration of images. IEEE Trans on PAMI 6:721-741, 1984.
60. Monaco JP, Tomaszewski JE, Feldman MD, Moradi M, Mousavi P, Boag A, Davidson C, Abolmaesumi P, Madabhushi A. Detection of prostate cancer from whole-mount histology images using Markov Random Fields. Workshop on Microscopic Image Analysis with Applications in Biology (in conjunction with MICCAI), 2008.
61. Lee G, Rodriguez C, Madabhushi A. An empirical comparison of dimensionality reduction methods for classifying gene and protein expression datasets. IEEE/ACM Trans Comput Biol Bioinform 5(3):170-181, 2008.
62. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 95(8):1146-1152, 2005.
63. Doyle S, Hwang M, Shah K, Feldman M, Tomaszewski J, Madabhushi A. Automated grading of prostate cancer using architectural and textural image features. Proc IEEE Int Symp Biomed Imaging 1284-1287, 2007.
64. Basavanhally AN, Agner S, Alexe G, Bhanot G, Ganesan S, Madabhushi A. Manifold learning with graph-based features for identifying extent of lymphocytic infiltration from high grade breast cancer histology. Workshop on Microscopic Image Analysis with Applications in Biology (in conjunction with MICCAI), 2008.
65. Doyle S, Agner S, Madabhushi A, Feldman M, Tomaszewski J. Automated grading of breast cancer histopathology using spectral clustering with textural and architectural image features. In: 2008 IEEE International Symposium on Biomedical Imaging: From Nano to Macro, May 14-17, 2008, Paris, France, pp496-499. New York: IEEE, 2008.
66. Varma M, Zisserman A. A statistical approach to texture classification from single images. Int J Comput Vis 62(1-2):61-81, 2005.
67. Wall ME, Rechtsteiner A, Rocha LM. Singular value decomposition and principal component analysis. In: Berrar DP, Dubitzky W, Granzow M, Eds. A Practical Approach to Microarray Data Analysis. New York: Kluwer, pp91-109, 2003.
68. Hartigan JA. Clustering. Annu Rev Biophys Bioeng 2:81-101, 1973.
69. Karypis G, Kumar V. Multilevel graph partitioning schemes. 24th International Conference on Parallel Processing. New York: CRC Press, pp113-122, 1995.
70. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc, Series B39:1-38, 1977.
71. Fraley B, Raftery AE. Model-based clustering, discriminant analysis, and density estimation. J Am Stat Assoc 97:611-631, 2002.
72. Cheeseman P, Kelly J, Self M, Stutz J, Taylor W, Freeman D. AutoClass: A Bayesian classification system. The Fifth International Conference on Machine Learning, Ann Arbor, MI. San Francisco: Morgan Kaufmann Publishers, pp54-64, 1988.
73. Cheng CH, Fu AW, Zhang Y. Entropy-based subspace clustering for mining numerical data. ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD-99). San Diego, 1999.
74. Kohonen T. Self-Organizing Maps. Berlin, Heidelberg, New York: Springer, 2001.